Johns Hopkins tests KRAS vaccine in 20 people at high pancreatic cancer risk: 90% immune response
In a small early-stage study, an experimental KRAS vaccine was safe and triggered an immune response in 90% of 20 high-risk participants. Whether it prevents cancer remains unknown.
Scientists at Johns Hopkins University are testing whether a vaccine can help prevent pancreatic cancer, according to knowridge.com. The work is at an early stage: a small study enrolled 20 people at increased risk of the disease. The vaccine appeared safe and produced an immune response in 90% of participants knowridge.com
knowridge.comknowridge.comOpen source ↗.
Pancreatic cancer is hard to treat because it often causes few clear symptoms until it has spread. Researchers hope that detecting cell changes much earlier could make prevention possible.
KRAS target and study results
The vaccine is designed to help the immune system notice changes in the KRAS gene. Such changes appear in more than 90% of pancreatic cancers and can begin years before a tumor develops.
Some of the immune cells linked to the response were still detectable up to two years later. None of the participants developed pancreatic cancer during follow-up. However, the group was far too small to show whether the vaccine prevented any cases knowridge.com
knowridge.comknowridge.comOpen source ↗.
Wider context for cancer vaccines
Ordinary vaccines prepare the body to fight germs, while cancer vaccines try to teach it to recognize unusual features of cancer cells. The pancreatic work is part of decades of research on this approach.
In melanoma, a large late-stage trial of a vaccine tailored to each patient reported better outcomes. This gives stronger evidence that the approach can help treat existing disease. Researchers are also studying vaccine combinations for liver cancer; the results are described as promising but preliminary.
Oncologist Mark Yarchoan discussed these developments in an editorial published November 11, 2026, in the New England Journal of Medicine knowridge.com
knowridge.comknowridge.comOpen source ↗. One reason for progress is that doctors can now identify changes inside tumors more precisely. They can also pair vaccines with drugs that help the immune system keep fighting rather than becoming less active.
The pancreatic results are not a ready-made prevention shot. Studies must follow many more people for longer before it is known whether the strategy saves lives.
